Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02731521 · ClinicalTrials.gov registry record
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 112
- Enrollment target
NCT02731521 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 112 participants.
The verdict
NCT02731521 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 112 participants
- Enrollment target
Study Summary
The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.
Interventions
- DEVICE 3 Tesla Scanning
- DEVICE 7 Tesla Scanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2014-01 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02731521
The ClinicalTrials.gov registry entry for NCT02731521 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3 Tesla Scanning is the first listed.
NCT02731521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02731521 about?
NCT02731521 is a clinical study titled "Clinical Development of MR Spectroscopy and Imaging in Brain Cancers". The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.
What is the current status of trial NCT02731521?
This trial is currently completed. The enrollment target is 112 participants. The study started on 2014-01. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02731521?
The interventions under investigation include: 3 Tesla Scanning (DEVICE), 7 Tesla Scanning (DEVICE).
Who is sponsoring clinical trial NCT02731521?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.